Ascentage Pharma Group International - ESG Rating & Company Profile powered by AI
Check the end of this webpage for potential risks for Ascentage Pharma Group International based on industry, geography and marketcap. This analysis of Ascentage Pharma Group International is assembled by All Street Sevva using leading AI. This webpage is a zero-cost E,S&G report covering Ascentage Pharma Group International.
Ascentage Pharma Group International in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.5; made up of an environmental score of 8.0, social score of 8.0 and governance score of 6.4.
7.5
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 149 | Torrent Pharmaceuticals Ltd | 7.6 | High |
| 149 | Virbac SA | 7.6 | High |
| 160 | Ascentage Pharma Group International | 7.5 | High |
| 160 | C4X Discovery Holdings PLC | 7.5 | High |
| 160 | Kindred Biosciences Inc | 7.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ascentage Pharma Group International have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose current and historical energy intensity?
Sign up for free to unlockDoes Ascentage Pharma Group International report the average age of the workforce?
Sign up for free to unlockDoes Ascentage Pharma Group International reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose cybersecurity risks?
Sign up for free to unlockDoes Ascentage Pharma Group International offer flexible work?
Sign up for free to unlockDoes Ascentage Pharma Group International have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ascentage Pharma Group International conduct supply chain audits?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ascentage Pharma Group International conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose water use targets?
Sign up for free to unlockDoes Ascentage Pharma Group International have careers partnerships with academic institutions?
Sign up for free to unlockDid Ascentage Pharma Group International have a product recall in the last two years?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose incidents of discrimination?
Sign up for free to unlockDoes Ascentage Pharma Group International allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ascentage Pharma Group International issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose parental leave metrics?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ascentage Pharma Group International support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ascentage Pharma Group International reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ascentage Pharma Group International involved in embryonic stem cell research?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose its waste policy?
Sign up for free to unlockDoes Ascentage Pharma Group International report according to TCFD requirements?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose energy use targets?
Sign up for free to unlockDoes Ascentage Pharma Group International disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ascentage Pharma Group International have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ascentage Pharma Group International
These potential risks are based on the size, segment and geographies of the company.
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.